Ipsen Logo

Ipsen

Developing innovative medicines for Oncology, Rare Diseases, and Neuroscience.

IPN | PA

Overview

Corporate Details

ISIN(s):
FR0010259150 (+17 more)
LEI:
549300M6SGDPB4Z94P11
Country:
France
Address:
65 QUAI GEORGES GORSE, 92100 BOULOGNE-BILLANCOURT
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Ipsen is a global biopharmaceutical company focused on developing and commercializing innovative medicines in specialty care. The company concentrates its efforts on three key therapeutic areas: Oncology, Rare Diseases, and Neuroscience. Ipsen's strategy targets conditions with high unmet medical needs, leveraging its global infrastructure, scientific expertise, and strategic partnerships to accelerate its research pipeline and bring transformative treatments to patients worldwide. The company is committed to advancing science with the purpose of improving health outcomes for underserved patient populations.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-07 18:30
Transaction in Own Shares
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - …
English 84.4 KB
2025-10-07 18:30
Transaction in Own Shares
IPSEN - Buy-back programme - Art 5 of MAR - Week 40 - 2025
English 85.2 KB
2025-09-30 18:30
Transaction in Own Shares
IPSEN - Buy-back programme - Art 5 of MAR - Week 39 - 2025
English 81.9 KB
2025-09-30 18:30
Transaction in Own Shares
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - …
English 81.3 KB
2025-09-16 18:30
Transaction in Own Shares
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - …
English 86.5 KB
2025-09-16 18:30
Transaction in Own Shares
IPSEN - Buy-back programme - Art 5 of MAR - Week 37 - 2025
English 86.4 KB
2025-09-02 18:00
Transaction in Own Shares
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - …
English 269.9 KB
2025-09-02 18:00
Transaction in Own Shares
IPSEN - Buy-back programme - Art 5 of MAR - Week 35 - 2025
English 542.0 KB
2025-07-10 18:30
Declaration of Voting Results & Voting Rights Announcements
Ipsen - Juin 2025 - Information mensuelle relative au nombre total des droits d…
French 124.2 KB
2025-07-10 18:30
Declaration of Voting Results & Voting Rights Announcements
Ipsen - June 2025 - Monthly information relative to the total number of voting …
English 106.7 KB
2025-07-01 09:00
Environmental & Social Information
Gemeinsam fur eine bessere Zukunft: Ipsen Pharma GmbH engagiert sich am Communi…
German 8.6 KB
2025-06-17 18:00
Transaction in Own Shares
IPSEN - Buy-back programme - Art 5 of MAR - Week 24 - 2025
English 271.6 KB
2025-06-17 18:00
Transaction in Own Shares
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - …
English 468.0 KB
2025-06-13 18:00
Transaction in Own Shares
IPSEN - Buy-back programme - Art 5 of MAR - Week 23 - 2025
English 324.3 KB
2025-06-13 18:00
Transaction in Own Shares
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - …
English 293.1 KB

Automate Your Workflow. Get a real-time feed of all Ipsen filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Ipsen

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Ipsen via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-09-04 N/A Other Sell 850 91,374.66 EUR
2024-02-27 N/A Other Buy 500 51,916.20 EUR
2023-07-31 N/A Other Buy 50,048 N/A

Peer Companies

PURPLE BIOTECH LTD. Logo
Develops first-in-class therapies targeting tumor immune evasion and drug resistance in cancer.
United States of America
PPBT
Pyxis Oncology, Inc. Logo
Developing next-gen ADC and Immuno-Oncology therapeutics for difficult-to-treat cancers.
United States of America
PYXS
PZ Cormay S.A. Logo
Manufactures and distributes IVD reagents and analyzers for human and veterinary medicine.
Poland
CRM
Q32 Bio Inc. Logo
Clinical-stage biotech developing biologic therapies for autoimmune and inflammatory diseases.
United States of America
QTTB
Quantum Biopharma Ltd. Logo
Develops therapies for brain disorders and a functional beverage for post-alcohol wellness.
United States of America
QNTM
Quantum Genomics Logo
Biopharma developing cardiovascular treatments, now in judicial liquidation.
France
ALQGC
QuidelOrtho Corp Logo
Manufactures in-vitro diagnostic tests for at-home, point-of-care, and clinical lab settings.
United States of America
QDEL
Quince Therapeutics, Inc. Logo
Late-stage biotech developing red blood cell-encapsulated drugs for rare diseases.
United States of America
QNCX
Quoin Pharmaceuticals, Ltd. Logo
Clinical-stage pharma developing therapies for rare and orphan diseases like Netherton Syndrome.
United States of America
QNRX
Quratis Inc. Logo
Develops infectious disease vaccines and offers biologics CDMO services for global health.
South Korea
348080

Talk to a Data Expert

Have a question? We'll get back to you promptly.